Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
This article was originally published in PharmAsia News
Executive Summary
A cholesterol drug Takeda had planned to file in the first quarter of 2008 has been delayed after elevated transaminase levels were seen in some patients taking a higher dose of the product in clinical trials, the Japanese firm announced Oct. 29. FDA has requested additional clinical trial data on TAK-475 (lapaquistat), a squalene synthase inhibitor
You may also be interested in...
Takeda Discontinues Development Of Cholesterol Compound
Takeda halted development of an investigational drug, TAK-475 (lapaquistat), for the treatment of high cholesterol, based on efficacy and safety data, the company announced March 28.
Takeda Discontinues Development Of Cholesterol Compound
Takeda halted development of an investigational drug, TAK-475 (lapaquistat), for the treatment of high cholesterol, based on efficacy and safety data, the company announced March 28.
Actos Franchise Drives Takeda's Pharmaceutical Sales Growth
Higher sales of Actos (pioglitazone) products were the prime driver behind a 7.7 percent increase in Takeda's pharmaceuticals segment for the nine months ending Dec. 31, 2007, compared with the same period in 2006, the company reported Jan. 31.